$TNGX News
Last published 1d ago
- 1d agoTNGXGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - TANGO THERAPEUTICS INCEarnings Call Transcriptswith Tango Therapeutics this morning. I'm Michael Schmitt, senior biotech analyst with Guggenheim. And with us today, we have Malte Peters, CEO of Tango. Malte, welcome, and thanks for joining us. Thanks, Michael, for ha
- 1d agoTNGXTANGO THERAPEUTICS, INC. (TNGX) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - TANGO THERAPEUTICS INCEarnings Call Transcriptswith Tango Therapeutics this morning. I'm Michael Schmitt, senior biotech analyst with Guggenheim. And with us today, we have Malte Peters, CEO of Tango. Malte, welcome, and thanks for joining us. Thanks, Michael, for ha
- 2d agoTNGXTango Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoTNGXTango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsGlobeNewswirePromising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in
- 1w agoTNGXERASTango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015GlobeNewswireBOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve
- 1w agoTNGXTango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation ConferenceGlobeNewswireBOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a
- 2w agoTNGXTango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development StrategyGlobeNewswire82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib Vopimetostat
- 3w agoTNGXTango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026GlobeNewswireBOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today
- 2mo agoTNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango
- 2mo agoTNGXTango Therapeutics to Participate in the 2026 Cantor Global Healthcare ConferenceGlobeNewswireBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX) ("Tango Therapeutics" or the "Company") today announced that members of the management team are scheduled to
- 3mo agoNTHITNGXINTSNeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight FloatGlobeNewswireDENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near
- 3mo agoTNGXTango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsGlobeNewswireCompany continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of
- 3mo agoTNGXTango Therapeutics Announces Executive Chair TransitionGlobeNewswireBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today
- 4mo agoTNGXTango Therapeutics Appoints Robert Azelby to Board of DirectorsGlobeNewswireBOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today
- 5mo agoTNGXTango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingGlobeNewswireBOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer
- 5mo agoTNGXTango Therapeutics Announces Proposed $500 Million Public OfferingGlobeNewswireBOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer
- 5mo agoTNGXTango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerGlobeNewswireInitial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of
- 5mo agoTNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective June 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a
- 6mo agoTNGXTango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsGlobeNewswireFirst clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13,
- 6mo agoTNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a
- 7mo agoTNGXTango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatGlobeNewswire- Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Tango
- 8mo agoTNGXTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a
- 8mo agoERASTNGXErasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and VopimetostatGlobeNewswireERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026
- 8mo agoTNGXTango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business HighlightsGlobeNewswireInitial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment New clinical supply agreement
- 8mo agoTNGXTango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor ConferencesGlobeNewswireBOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial
- 9mo agoTNGXTango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireBOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a
- 10mo agoTNGXTango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed SuccessorGlobeNewswireFounding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08,
- 10mo agoTNGXTango Therapeutics Appoints Sung Lee to Board of DirectorsGlobeNewswireBOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today
- 10mo agoTNGXTango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a
- 11mo agoONCYIMRXTNGXMRNA+1Pancreatic Cancer Survival Gains Accelerate as Novel Therapies AdvancePR NewswireUSANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by...
- 11mo agoTNGXTango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireBOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to
- 12mo agoTNGXTango Therapeutics to Participate in the 2025 Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a
- 1y agoTNGXTango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswire– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%
- 1y agoTNGXTango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025GlobeNewswireBOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.
- 1y agoTNGXTango Therapeutics Announces $225 Million FinancingGlobeNewswireBOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,
- 1y agoTNGXTango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted CancersGlobeNewswire– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%
- 1y agoTNGXTango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025GlobeNewswireBOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today
- 1y agoTNGXTango Therapeutics to Participate in the 2025 Cantor Global Healthcare ConferenceGlobeNewswireBOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a
- 1y agoTNGXTango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswire– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in
- 1y agoTNGXTango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025GlobeNewswireBOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial
- 1y agoTNGXTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerGlobeNewswireBOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that
- 1y agoTNGXTango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewswireBOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a
- 1y agoTNGXTango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid TumorsGlobeNewswireBOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that
- 1y agoTNGXTango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswire– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million
- 1y agoTNGXTango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025GlobeNewswireBOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets.
- 1y agoBNTXGSKNVSRLAY+2Barbara Weber, M.D., Elected to ITM Supervisory BoardGlobeNewswireGarching / Munich, Germany, April 09, 2025 –
- 1y agoTNGXTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewswireBOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today
- 1y agoTNGXTango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business HighlightsGlobeNewswire– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA.
- 1y agoTNGXTango Therapeutics to Present at Three Upcoming Investment Bank ConferencesGlobeNewswireBOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer
- 1y agoTNGXTango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology ConferenceGlobeNewswireBOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today